Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Journal of Neuro-Oncology
Erschienen in: Journal of Neuro-Oncology 3/2020

12.08.2020 | Topic Review

Radiation therapy strategies for skull-base malignancies

verfasst von: J. D. Palmer, M. E. Gamez, K. Ranta, H. Ruiz-Garcia, J. L. Peterson, D. M. Blakaj, D. Prevedello, R. Carrau, A. Mahajan, K. L. Chaichana, D. M. Trifiletti

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The management of skull base malignancies continues to evolve with improvements in surgical technique, advances in radiation delivery and novel systemic agents.

Methods

In this review, we aim to discuss in detail the management of common skull base pathologies which typically require multimodality therapy, focusing on the radiotherapeutic aspects of care.

Results

Technological advances in the administration of radiation therapy have led to a wide variety of different treatment strategies for the treatment of skull base malignances, with outcomes summarized herein.

Conclusion

Radiation treatment plays a key and critical role in the management of patients with skull base tumors. Recent advancements continue to improve the risk/benefit ratio for radiotherapy in this setting.
Literatur
1.
Wang H, Yang JN, Zhang XD et al (2019) Treatment-plan comparision of three advanced radiation treatment modalities for fractionated stereotactic radiotherapy to the head and neck. Int J Med Phys 8:106–120
2.
Sturgis EM, Potter BO (2003) Sarcomas of the head and neck region. Curr Opin Oncol 15:239–252PubMed
3.
De Bree R, Van Der Waal I, De Bree E et al (2010) Management of adult soft tissue sarcomas of the head and neck. Oral Oncol 46:786–790PubMed
4.
Wu AW, Suh JD, Metson R et al (2012) Prognostic factors in sinonasal sarcomas: analysis of the surveillance, epidemiology and end result database. Laryngoscope 122:2137–2142PubMed
5.
Szablewski V, Neuville A, Terrier P et al (2015) Adult sinonasal soft tissue sarcoma: analysis of 48 cases from the French Sarcoma Group database. Laryngoscope 125:615–623PubMed
6.
Pamir MN, Ozduman K (2006) Analysis of radiological features relative to histopathology in 42 skull-base chordomas and chondrosarcomas. Eur J Radiol 58:461–470PubMed
7.
Welzel T, Meyerhof E, Uhl M et al (2018) Diagnostic accuracy of DW MR imaging in the differentiation of chordomas and chondrosarcomas of the skull base: A 3.0-T MRI study of 105 cases. Eur J Radiol 105:119–124PubMed
8.
Li L, Wang K, Ma X et al (2019) Radiomic analysis of multiparametric magnetic resonance imaging for differentiating skull base chordoma and chondrosarcoma. Eur J Radiol 118:81–87PubMed
9.
Santegoeds RGC, Temel Y, Beckervordersandforth JC et al (2018) State-of-the-art imaging in human chordoma of the skull base. Curr Radiol Rep 6(5):16PubMedPubMedCentral
10.
Weber DC, Malyapa R, Albertini F et al (2016) Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. Radiother Oncol 120:169–174PubMed
11.
Bakker SH, Jacobs WCH, Pondaag W et al (2018) Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival. Eur Spine J 27:3043–3058PubMed
12.
Amit M, Na'ara S, Binenbaum Y et al (2014) Treatment and outcome of patients with skull base chordoma: a meta-analysis. J Neurol Surg B 75:383–390
13.
Di Maio S, Temkin N, Ramanathan D et al (2011) Current comprehensive management of cranial base chordomas: 10-year meta-analysis of observational studies. J Neurosurg 115:1094–1105PubMed
14.
Bloch O, Parsa AT (2013) Skull base chondrosarcoma: evidence-based treatment paradigms. Neurosurg Clin N Am 24:89–96PubMed
15.
Van Gompel JJ, Janus JR (2015) Chordoma and chondrosarcoma. Otolaryngol Clin N Am 48:501–514
16.
Komotar RJ, Starke RM, Raper DM et al (2011) The endoscope-assisted ventral approach compared with open microscope-assisted surgery for clival chordomas. World Neurosurg 76:318–327PubMed
17.
Di Maio S, Rostomily R, Sekhar LN (2012) Current surgical outcomes for cranial base chordomas: cohort study of 95 patients. Neurosurgery 70:1355–1360PubMed
18.
Tzortzidis F, Elahi F, Wright DC et al (2006) Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chondrosarcomas. Neurosurgery 58:1090–1098PubMed
19.
Stacchiotti S, Gronchi A, Fossati P et al (2017) Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. Ann Oncol 28:1230–1242PubMedPubMedCentral
20.
Stacchiotti S, Sommer J (2015) Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol 16:e71–83PubMed
21.
Iyer A, Kano H, Kondziolka D et al (2013) Postsurgical management strategies in patients with skull base chondrosarcomas. CNS Oncol 2:203–208PubMedPubMedCentral
22.
Bloch OG, Jian BJ, Yang I et al (2009) A systematic review of intracranial chondrosarcoma and survival. J Clin Neurosci 16:1547–1551PubMedPubMedCentral
23.
Rosenberg AE, Nielsen GP, Keel SB et al (1999) Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol 23:1370–1378PubMed
24.
Almefty K, Pravdenkova S, Colli BO et al (2007) Chordoma and chondrosarcoma: similar, but quite different, skull base tumors. Cancer 110:2457–2467PubMed
25.
Raza SM, Gidley PW, Meis JM et al (2017) Multimodality treatment of skull base chondrosarcomas: the role of histology specific treatment protocols. Neurosurgery 81:520–530PubMed
26.
Kano H, Niranjan A, Lunsford LD (2019) Radiosurgery for chordoma and chondrosarcoma. Prog Neurol Surg 34:207–214PubMed
27.
Uhl M, Mattke M, Welzel T et al (2014) High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results. Cancer 120:1579–1585PubMed
28.
Feuvret L, Bracci S, Calugaru V et al (2016) Efficacy and safety of adjuvant proton therapy combined with surgery for chondrosarcoma of the skull base: a retrospective, population-based study. Int J Radiat Oncol Biol Phys 95:312–321PubMed
29.
30.
Ahmed SK, Brown PD, Foote RL (2018) Protons vs photons for brain and skull base tumors. Semin Radiat Oncol 28:97–107PubMed
31.
McDonald MW, Linton OR, Moore MG et al (2016) Influence of residual tumor volume and radiation dose coverage in outcomes for clival chordoma. Int J Radiat Oncol Biol Phys 95:304–311PubMed
32.
Raza SM, Bell D, Freeman JL et al (2018) Multimodality management of recurrent skull base chordomas: factors impacting tumor control and disease-specific survival. Oper Neurosurg (Hagerstown) 15:131–143
33.
Alahmari M, Temel Y (2019) Skull base chordoma treated with proton therapy: a systematic review. Surg Neurol Int 10:96PubMedPubMedCentral
34.
Nikoghosyan AV, Karapanagiotou-Schenkel I, Munter MW et al (2010) Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study. BMC Cancer. 10:607PubMedPubMedCentral
35.
Munzenrider JE, Liebsch NJ (1999) Proton therapy for tumors of the skull base. Strahlenther Onkol 175:57–63PubMed
36.
Uhl M, Mattke M, Welzel T et al (2014) Highly effective treatment of skull base chordoma with carbon ion irradiation using a raster scan technique in 155 patients: first long-term results. Cancer 120:3410–3417PubMed
37.
Mattke M, Vogt K, Bougatf N et al (2018) High control rates of proton- and carbon-ion-beam treatment with intensity-modulated active raster scanning in 101 patients with skull base chondrosarcoma at the Heidelberg Ion Beam Therapy Center. Cancer 124:2036–2044PubMed
38.
Frezza AM, Cesari M, Baumhoer D et al (2015) Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur J Cancer 51:374–381PubMed
39.
Italiano A, Mir O, Cioffi A et al (2013) Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol 24:2916–2922PubMedPubMedCentral
40.
Stacchiotti S, Longhi A, Ferraresi V et al (2012) Phase II study of imatinib in advanced chordoma. J Clin Oncol 30:914–920PubMed
41.
Stacchiotti S, Morosi C, Lo Vullo S et al (2018) Imatinib and everolimus in patients with progressing advanced chordoma: a phase 2 clinical study. Cancer 124:4056–4063PubMed
42.
Vujovic S, Henderson S, Presneau N et al (2006) Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 209:157–165PubMed
43.
Gill CM, Fowkes M, Shrivastava RK (2019) Emerging therapeutic targets in chordomas: a review of the literature in the genomic era. Neurosurgery 86(2):E118–E123
44.
Eilber FC, Dry SM (2008) Diagnosis and management of synovial sarcoma. J Surg Oncol 97(4):314–320PubMed
45.
Palmerini E, Staals EL, Alberghini M et al (2009) Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer 115(13):2988–2998PubMed
46.
Harb WJ, Luna MA, Patel SR et al (2007) Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension. Head Neck 29(8):731–740PubMed
47.
Al-Daraji W, Lasota J, Foss R et al (2009) Synovial sarcoma involving the head: analysis of 36 cases with predilection to the parotid and temporal regions. Am J Surg Pathol 33(10):1494–1503PubMed
48.
Cihak RA, Lydiatt WM, Lydiatt DD et al (1997) Synovial sarcoma of the head and neck: chromosomal translocation (x;18) as a diagnostic aid. Head Neck 19:549–553PubMed
49.
WHO (2020) WHO classification of soft tissue and bone tumors, vol 3, 5th edn. International Agency for Research on Cancer, Lyon
50.
Mullen JR, Zagars GK (1994) Synovial sarcoma outcome following conservation surgery and radiotherapy. Radiother Oncol 33(1):23–30PubMed
51.
Colville RJ, Charlton F, Kelly CG et al (2005) Multidisciplinary management of head and neck sarcomas. Head Neck 27:814–824PubMed
52.
Shmookler BM, Enzinger FM, Brannon RB et al (1982) Orofacial synovial sarcoma: a clinicopathologic study of 11 new canses and review of literature. Cancer 50:269–276PubMed
53.
Ji T, Ma CY, Ow A et al (2011) Synovial sarcoma involving skull base—a retrospective analysis of diagnosis and treatment of 21 cases in one institution. Oral Oncol 47:671–676PubMed
54.
Lee N, Shin E (2008) Treatment outcomes for patients with synovial sarcoma of the head and neck. Expert Rev Anticancer Ther 8(3):371–373PubMed
55.
Clair JM, Arshi A, Abemayor E et al (2016) Synovial cell sarcoma of the head and neck: an analysis of 167 cases using the SEER database. JAMA Otolaryngol Head Neck Surg 142(6):576–583PubMedCentral
56.
Siegal GP, Oliver WR, Reinus WR et al (1987) Primary Ewing’s sarcoma involving the bones of the head and neck. Cancer 60(11):2829–2840PubMed
57.
Choi EY, Gardner JM, Lucas DR et al (2014) Ewing sarcoma. Semin Diagn Pathol 31(1):39–47PubMed
58.
Desai KI, Nadkami TD, Goel A et al (2000) Primary Ewing’s sarcoma of the cranium. Neurosurgery 46(1):62–68PubMed
59.
Womer RB, West DC, Krailo MD et al (2012) Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 30(33):4148–4154PubMedPubMedCentral
60.
Mascarenhas L, Felgenhauer JL, Bond MC et al (2016) Pilot study of adding vincristine, topotecan, and cyclophosphamide to interval compressed chemotherapy in newly diagnosed patients with localized Ewing sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 63(3):493–498PubMed
61.
Biswas B, Thakar A, Mohanti BK et al (2015) Prognostic factors in head and neck Ewing sarcoma family to tumors. Laryngoscope 125:E112–E117PubMed
62.
Olson MD, Van Abel KM, Wehrs RN et al (2018) Ewing sarcoma of the head and neck: the Mayo Clinic experience. Head Neck 40(9):1999–2006PubMed
63.
Kharod SM, Indelicato DJ, Rotondo RL et al (2020) Outcomes following proton therapy for Ewing sarcoma of the cranium and skull base. Pediatr Blood Cancer 67(2):e28080PubMed
64.
Patel AJ, Rao VY, Fox BD et al (2011) Radiation-induced osteosarcomas of the calvarium and skull base. Cancer 117:2120–2126PubMed
65.
Wu G, Liang Q, Liu Y (2017) Primary osteosarcoma of the frontal bone. Medicine (Baltimore) 96(51):e9392
66.
Caron AS, Hajdu SI, Strong EW (1971) Osteogenic sarcoma of the facial and cranial bones. A review of forty-three cases. Am J Surg 122:719–725PubMed
67.
Guo Z, Hu K, Zhao B et al (2017) Osteosarcoma of the skull base: an analysis of 19 cases and literature review. J Clin Neurosci 44:133–142PubMed
68.
Chen Y, Shen Q, Gokavarapu S et al (2016) Osteosarcoma of head and neck: a retrospective study on prognostic factors from a single institute database. Oral Oncol 58:1–7PubMed
69.
Smith RB, Apostolakis LW, Karnell LH et al (2003) National cancer data base report on osteosarcoma of the head and neck. Cancer 98:1670–1680PubMed
70.
Ciernik FI, Niemierko A, Harmon DC et al (2011) Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 117(19):4522–4530PubMed
71.
DeLaney TF, Park L, Goldberg SI et al (2005) Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 61(2):492–498PubMed
72.
Lewis JT, Oliveira AM, Nascimento AG et al (2012) Low-grade sinonasal sarcoma with neural and myogenic features: a clinicopathologic analysis of 28 cases. Am J Surg Pathol 36(4):517–525PubMed
73.
Stelow EB, Bishop JA (2017) Update from the 4th edition of the World Health Organization classification of head and neck tumours: tumors of the nasal cavity, paranasal sinuses and skull base. Head and Neck Pathol 11:3–15
74.
Carter CS, East EG, McHugh JB (2018) Biphenotypic sinonasal sarcoma: a review and update. Arch Pathol Lab Med 142(10):1196–1201PubMed
75.
Rooper LM, Huang SC, Antonescu CR et al (2016) Biphenotypic sinonasal sarcoma: an expanded immunoprofile including consistent nuclear beta-catenin positivity and absence of SOX10 expression. Hum Pathol 55:44–50PubMedPubMedCentral
76.
Fritchie KJ, Jin L, Wang X et al (2016) Fusion gene profile of biphenotypic sinonasal sarcoma: an analysis of 44 cases. Histophatology 69(6):930–936
77.
Miglani A, Lal D, Weindling SM et al (2019) Imaging characteristics and clinical outcomes of biphenotypic sinonasal sarcoma. Laryngoscope Investig Otolaryngol 4(5):484–488PubMedPubMedCentral
78.
Kuhn AL, Jalisi S, Nishin M et al (2019) Biphenotypic sinonasal sarcoma—description of radiologic, intraoperative and pathologic findings. Otolaryngol Case Rep 11:100113
79.
Siddiqui F, Smith RV, Yom SS et al (2017) ACR appropriateness criteria nasal cavity and paranasal sinus cancers. Head Neck 39(3):407–418PubMed
80.
Cannon RB, Wiggins RH III, Witt BL et al (2017) Imaging and outcomes for a new entity: low-grade sinonasal sarcoma with neural and myogenic features. J Neurol Surg Rep 78:e15–e19PubMedPubMedCentral
81.
Wagner E (1870) Das tuberkelahnliche lymphadenom (der cytogene oder reticulirte tuberkel). Arch Heilk (Leipig) 11:497
82.
Gengler C, Guillou L (2006) Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology 48:63–74PubMed
83.
Schiariti M, Goetz P, El-Maghraby H et al (2011) Hemangiopeericytoma: long-term outcome revisited. J Neurosurg 114(3):747–755PubMed
84.
Stout AP, Murray MR (1942) Hemangiopericytoma a vascular tumor featuring Zimmermann’s pericytes. Ann Surg 116(1):26–33PubMedPubMedCentral
85.
Fritchie KJ, Jin L, Rubin BP et al (2016) NAB2-STAT6 gene fusion in meningeal hemangiopericytoma and solitary fibrous tumor. J Neuropathol Exp Neurol 75(3):263–271PubMed
86.
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820PubMed
87.
Ghia AJ, Chang EL, Allen PK et al (2013) Intracranial hemangiopericytoma: patterns of failure and the role of radiation therapy. Neurosurgery 73(4):624–630PubMed
88.
Sonabend AM, Zacharia BE, Goldstein H et al (2014) The role of adjuvant radiotherapy in the treatment of hemangiopericytoma: a surveillance, epidemiology, and end results analysis. J Neurosurg 120(2):300–308PubMed
89.
Patel AR, Flores BC, Ban VS et al (2017) Intracranial hemangiopericytomas: recurrence, metastasis, and radiotherapy. J Neurol Surg B 78(4):324–330
90.
Combs SE, Thilmann C, Debus J et al (2005) Precision radiotherpay for hemangiopericytomas of the central nervous system. Cancer 104(11):2457–2465PubMed
91.
George S, Merriam P, Maki RG et al (2009) Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 27(19):3154–3160PubMedPubMedCentral
92.
Valentin T, Fournier C, Penel N et al (2013) Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Investig New Drugs 31(6):1626–1627
93.
Park MS, Patel SR, Ludwig JA et al (2011) Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangoipericytoma and malignant solitary fibrous tumor. Cancer 117(21):4939–4947PubMed
94.
Batsakis JG, Rice DH, Solomon AR (1980) The pathology of head and neck tumors: squamous and mucous-gland carcinomas of the nasal cavity, paranasal sinuses, and larynx, part 6. Head Neck Surg 2:497–508PubMed
95.
Ayiomamitis A, Parker L, Havas T (1988) The epidemiology of malignant neoplasms of the nasal cavities, the paransal sinues and the middle ear in Canada. Arch Otorhinolaryngol 244:367–371PubMed
96.
Turner JH, Reh DD (2012) Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck 34(6):877–885PubMed
97.
Abu-Ghanem S, Horowitz G, Abergel A et al (2015) Elective neck irradiation versus observation in squamous cell carcinoma of the maxillary sinus with N0 neck: a meta-analysis and review of the literature. Head Neck 37:1823–1828PubMed
98.
Faisal M, Seemann R, Lill C et al (2020) Elective neck treatment in sinonasal undifferentiated carcinoma: systematic review and meta-analysis. Head Neck 42:1057–1066PubMedPubMedCentral
99.
Jiang W, Mohamed ASR, Fuller CD et al (2016) The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Pract Radiat Oncol 6:241–247PubMed
100.
Song X, Huang C, Wang S et al (2020) Neck management in patients with olfactory neuroblastoma. Oral Oncol 101:104505PubMed
101.
Robin TP, Jones BL, Gordon OM et al (2017) A comprehensive analysis of treatment modalities for sinonasal malignancies. Cancer 123(16):3040–3049PubMed
102.
Wiegner EA, Daly ME, Murphy JD et al (2012) Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 83(1):243–251PubMed
103.
Al-Mamgani A, Monserez D, Van Rooij P et al (2012) Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation. Oral Oncol 48:905–911PubMed
104.
Toyomasu Y, Demizu Y, Matsuo Y et al (2018) Outcomes of patients with sinonasal squamous cell carcinoma treated with particle therapy using protons or carbon ions. Int J Radiat Oncol Biol Phys 5(1):1096–1103
105.
Daly ME, Chen AM, Bucci KM et al (2007) Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys 67(1):151–157PubMed
106.
Fan M, Kang JJ, Lee A et al (2020) Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies. Cancer 126(9):1905–1916PubMed
107.
Patel SH, Wang Z, Wong WW et al (2014) Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncol 15:1027–1038PubMed
108.
Zenda S, Kohno R, Kawashima M et al (2011) Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys 81(5):1473–1478PubMed
109.
Russo AL, Adams JA, Weyman EA et al (2016) Long-term outcomes after proton beam therapy for sinonasal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 95(1):368–376PubMed
110.
Dagan R, Bryant C, Li Z et al (2016) Outcomes of sinonasal cancer treated with proton therapy. Int J Radiat Oncol Biol Phys 95(1):377–385PubMed
111.
Yu NY, Gamez ME, Hartsell WF et al (2019) A multi-institutional experience of proton beam therapy for sinonasal tumors. Adv Radiat Oncol 4(4):689–698PubMedPubMedCentral
112.
Barnes L (1986) Intestinal-type adenocarcinoma of the nasal cavity and paranasal sinues. Am J Surg Pathol 10:192–202PubMed
113.
Leivo I (2016) Sinonasal adenocarcinoma: update on classification, immunophenotype and molecular features. Head Neck Pathol 10(1):68–74PubMedPubMedCentral
114.
Thompson LDR, Franchi A (2018) New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: nasal cavity, paranasal sinuses and skull base. Virchows Arch 472:315–330PubMed
115.
Lund VJ, Chisholm EJ, Takes RP et al (2012) Evidence for treatment strategeis in sinonasal adenocarcinoma. Head Neck 34:1168–1178PubMed
116.
Duprez F, Madani I, Morbee L et al (2012) IMRT for sinonasal tumors minimizes severe late ocular toxicity and preserves disease control and survival. Int J Radiat Oncol Biol Phys 83(1):252–259PubMed
117.
Fordice J, Kershaw C, El-Naggar A et al (1999) Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 125(2):149–152PubMed
118.
Lupinetti AD, Roberts DB, Williams MD et al (2007) Sinonasal adenoid cystic carcinoma: the M.D. Anderson Cancer Center experience. Cancer 110(12):2726–2731PubMed
119.
Bishop JA, Ogawa T, Stelow EB et al (2013) Human papillomavirus-related carcinoma with adenoid cystic-like features: a peculiar variant of head and neck restricted to the sinonasal tract. Am J Surg Pathol 37(6):836–844PubMedPubMedCentral
120.
Miller ED, Blakaj DM, Swanson BJ et al (2017) Sinonasal adenoid cystic carcinoma: treatment outcomes and association with human papillomavirus. Head Neck 39:1405–1411PubMedPubMedCentral
121.
Koto M, Demizu Y, Saitoh JI et al (2018) Definitive carbon-ion radiation therapy for locally advanced sinonasal malignant tumors: subgroup analysis of a multicenter study be the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS). Int J Radiat Oncol Biol Phys 102(2):353–361PubMed
122.
Frierson HF Jr, Mills SE, Fechner RE et al (1986) Sinonasal undifferentiated carcinoma. An aggressive neoplasm deivered from Schneiderian epithelium and distinct from olfactory neuroblastoma. Am J Surg Pathol 10(11):771–779PubMed
123.
Levine PA, Frierson HF Jr, Stewart FM et al (1987) Sinonasal undifferentiated carcinoma: a distinctive andhighly aggressive neoplasm. Laryngoscope 97(8 Pt 1):905–908PubMed
124.
Mendenhall WM, Mendenhall CM, Riggs CE Jr et al (2006) Sinonasal undifferentiated carcinoma. Am J Clin Oncol 29(1):27–31PubMed
125.
Mourad WF, Hauerstock D, Shourbaji RA et al (2013) Trimodality management of sinonasal undifferentiated carcinoma and review of the literature. Am J Clin Oncol 36(6):584–588PubMed
126.
Gamez ME, Lal D, Halyard MY et al (2017) Outcomes and patterns of failure for sinonasal undifferentiated carcinoma (SNUC): the Mayo Clinic experience. Head Neck 39:1819–1824PubMed
127.
Amit M, Abdelmeguid AS, Watcherporn T et al (2019) Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol 37:504–512PubMedPubMedCentral
128.
London N, Mohyeldin A, Daoud G et al (2020) Sinonasal undifferentiated carcinoma: an institutional trend towards induction chemotherapy followed by definitive chemoradiation. J Neurol Surg B 81(S 01):S1–S272
129.
Krishnamurthy A, Ravi P, Vijayalakshmi R et al (2013) Small cell neuroendocrine carcinoma of the paranasal sinus. Natl J Maxillofac Surg 4(1):111–113PubMedPubMedCentral
130.
Raychowdhuri RN (1965) Oat-cell carcinoma and paranasal sinuses. J Laryngol Otol 79:253–255PubMed
131.
Perez-Ordonez B, Caruana SM, Huvos AG et al (1998) Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. Hum Pathol 29:826–832PubMed
132.
Fitzek MM, Thornton AF, Varvares M et al (2002) Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer 94(10):2623–2634PubMed
133.
Rosenthal DI, Barker JL Jr, El-Naggar AK et al (2004) Sinonasal malignancies with neuroendocrine differentiation. Cancer 101:2567–2573PubMed
134.
Brennan SM, Gregory DL, Stillie A et al (2010) Should extrapulmonary small cell cancer be managed like small cell lung cancer? Cancer 116(4):888–895PubMed
135.
Babin E, Rouleau V, Vedrine PO et al (2006) Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinues. J Laryngol Otol 120(4):289–297PubMed
136.
Khan M, Nizami S, Mirrahimov AE et al (2014) Primary small cell neuroendocrine carcinoma of the paransal sinuses. Case Rep Med 2014:874719PubMedPubMedCentral
137.
Hosokawa S, Okamura J, Takizawa Y et al (2013) Long-term survival of a patient with primary small cell neuroendocrine carcinoma of the maxillary sinus: a case report. J Oral Maxillofac Surg 71(8):e248–252PubMed
138.
Salhab M, Migdady Y, Donahue M et al (2018) Immunohistochemical expression and prognostic value of PD-L1 in extrapulmonary small cell carcinoma: a single institution experience. J Immunother Cancer 6(1):42PubMedPubMedCentral
139.
Jethanamest D, Morris LG, Sikora AG et al (2007) Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg 133(3):276–280PubMed
140.
Ferlito A, Rinaldo A, Rhys-Evans PH (2003) Contemporary clinical commentary: esthesioneuroblastoma: an update on management of the neck. Laryngoscope 113:1935–1938PubMed
141.
Berger L, Luc G, Richard D (1924) The olfactory esthesioneuroepithelioma. Bull Assoc Franc Etude Cancer 13:410–421
142.
Kadish S, Goodman M, Wang CC (1976) Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 37(03):1571–1576PubMed
143.
Thompson LDR (2009) Olfactory neuroblastoma. Head and Neck Pathol 3:252–259
144.
Van Gompell JJ, Giannini C, Olsen KD et al (2012) Long-term outcome of esthesioneuroblastoma: hyams grade predicst patient survival. J Neurol Surg B 73(05):331–336
145.
Diaz EM Jr, Johnigan RH III, Pero C et al (2005) Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck 27(02):138–149PubMed
146.
Chao KS, Kaplan C, Simpson JR et al (2001) Esthesioneuroblastoma: the impact of treatment modality. Head Neck 23(09):749–757PubMed
147.
Resto VA, Eisele DW, Forastiere A et al (2000) Esthesioneuroblastoma: the Johns Hopkins experiene. Head Neck 22(06):550–558PubMed
148.
Dulguerov P, Calcaterra T (1992) Esthesioneuroblastoma: the UCLA experience 1970–1990. Laryngoscope 102(08):843–849PubMed
149.
150.
Platek ME, Merzianu M, Mashtare TL et al (2011) Improved survival following surgery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database. Radiat Oncol 6:41PubMedPubMedCentral
151.
Noh OK, Lee SW, Yoon SM et al (2011) Radiotherapy for esthesioneuroblastoma: is elective nodal irradiation warranted in the multiomodality treatment approach? Int J Radiat Oncol Biol Phys 79(02):443–449PubMed
152.
Monroe AT, Hinerman RW, Amdur RJ et al (2003) Radiation therapy for estehsioneuroblastoma: rationale for elective neck irradiation. Head Neck 25(7):529–534PubMed
153.
Beitler JJ, Fass DE, Brenner HA et al (1991) Esthesioneuroblastoma: is there a role for elective neck treatment? Head Neck 13:321–326PubMed
154.
Demiroz C, Gutfeld O, Aboziada M et al (2011) Esthesioneuroblastoma: is there a need for elective neck treatment? Int J Radiat Oncol Biol Phys 81(4):e255–e261PubMed
155.
Banuchi VE, Dooley L, Lee NY et al (2016) Patterns of regional and distant metastasis in esthesioneuroblastoma. Laryngoscope 126(7):1556–1561PubMedPubMedCentral
156.
Wolfe AR, Klamer B, Pan J et al (2018) The impact of adjuvant radiation therapy and elective nodal irradiation in early stage/low grade versus advanced stage/high grade olfactory neuroblastoma. Int J Radiat Oncol Biol Phys 102(3):E360–361
157.
Bauer DE, Mitchell CM, Strait KM et al (2012) Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 18(20):5773–5779PubMedPubMedCentral
158.
Alekseyenko AA, Walsh EM, Zee BM et al (2017) Ectopic protein interactions within BRD4 chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma. Proc Natl Acad Sci USA 114(21):E4184–E4192PubMedPubMedCentral
159.
Grayson AR, Walsh EM, Cameron MJ et al (2014) MYC, a downstream target of BRDNUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene 33(13):1736–1742PubMed
160.
Alekseyenko AA, Walsh EM, Wang X et al (2015) The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes Dev 29(14):1507–1523PubMedPubMedCentral
161.
French CA, Miyoshi I, Kubonishi I et al (2003) BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 63(2):304–307PubMed
162.
Vargas SO, French CA, Faul PN et al (2001) Upper respiratory tract carcinoma with chromosomal translocation 15;19: evidence for a distinct disease entity of young patients with a rapidly fatal course. Cancer 92:1195–1203PubMed
163.
Kees UR, Mulcahy MT, Willoughby ML et al (1991) Intrathoracic carcinoma in an 11-year old girl showing translocation t(15;19). Am J Pediatr Hematol Oncol 13:459–464PubMed
164.
Lee AC, Kwong YI, Fu KH et al (1993) Disseminated mediastinal carcinoma with chromosomal translocation (15;19): a distinctive clinicopathologic syndrome. Cancer 72:2273–2276PubMed
165.
166.
Salati M, Baldessari C, Boneti LR et al (2019) NUT midline carcinoma: current concepts and future perspectives of a novel tumour entity. Crit Rev Oncol Hematol 144:102826PubMed
167.
Napolitano M, Venturelli M, Molinaro E et al (2019) NUT midline carcinoma of the head and neck: current perspectives. Onco Targets Ther 12:3235–3244PubMedPubMedCentral
168.
Giridhar P, Mallick S, Kashyap L et al (2018) Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases. Eur Arch Otorhinolaryngol 275(3):815–821PubMed
169.
Chau NG, Ma C, Danga K et al (2019) An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients. JNCI Cancer Spectr 4(2):pkz094PubMedPubMedCentral
170.
171.
Stathis A, Zucca E, Bekradda M et al (2016) Clinical response of carcinomas harboring the BRD4-NUT oncoprotein fo the targeted bromodomain inhibitor OTX015/MK-8628. Cancer Discov 6:492–500PubMedPubMedCentral
172.
Piha-Paul SA, Hann CL, French CA et al (2020) Phase 1 study of Molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors. JNCI Cancer Spectr 4(2):pkz093PubMed
173.
Schwartz BE, Hofer MD, Lemieux ME et al (2011) Differentaition of NUT midline carcinoma by epigenomic reprogramming. Cancer Res 71:2686–2696PubMedPubMedCentral
174.
Combs SE, Adeberg S, Dittmar JO et al (2013) Skull base meningiomas: long-term results and patient self-reported outcome in 507 patients treated with fractionated stereotactic radiotherapy (FSRT) or intensity modulated radiotherapy (IMRT). Radiother Oncol 106:186–191PubMed
175.
Starke RM, Williams BJ, Hiles C et al (2012) Gamma knife surgery for skull base meningiomas. J Neurosurg 116:588–597PubMed
176.
Han J, Girvigian MR, Chen JC et al (2014) A comparative study of stereotactic radiosurgery, hypofractionated, and fractionated stereotactic radiotherapy in the treatment of skull base meningioma. Am J Clin Oncol 37:255–260PubMed
177.
El Shafie RA, Czech M, Kessel KA et al (2018) Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning. Radiat Oncol 13:54PubMedPubMedCentral
178.
Murray FR, Snider JW, Bolsi A et al (2017) Long-term clinical outcomes of pencil beam scanning proton therapy for benign and non-benign intracranial meningiomas. Int J Radiat Oncol Biol Phys 99:1190–1198PubMed
179.
Rogers CL, Zhang P, Vogelbaum MA et al (2018) Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 129(1):35–47PubMed
180.
Rogers CL, Won M, Vogelbaum MA et al (2020) High-risk meningioma: initial outcomes from NRG Oncology/RTOG 0539. Int J Radiat Oncol Biol Phys 106(4):790–799PubMed
181.
Kaley T, Barani I, Chamberlain M et al (2014) Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol 16:829–840PubMedPubMedCentral
182.
Goldbrunner R, Minniti G, Preusser M et al (2016) EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17:e383–391PubMed
183.
Sahm F, Schrimpf D, Stichel D et al (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18:682–694PubMed
184.
Nigim F, Wakimoto H, Kasper EM et al (2018) Emerging medical treatments for meningioma in the molecular era. Biomedicines 6(3):86PubMedCentral
185.
Sklar CA, Antal Z, Chemaitilly W et al (2018) Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol 103(8):2761–2784
186.
Pai HH, Thornton A, Katznelson L et al (2001) Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram anaylisis. Int J Radiat Oncol Biol Phys 49(4):1079–1092PubMed
187.
Kyriakakis N, Lynch J, Orme SM et al (2016) Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumors. Clin Endocrinol (Oxf) 84(3):372–379
188.
189.
Chemaitilly W, Cohen LE (2017) Diagnosis of endocrine disease: endocrine late-effects of childhood cancer and its treatments. Eur J Endocrinol 176(4):R183–R203PubMed
190.
Vatner RE, Niemierko A, Misra M et al (2018) Endocrine deficiency as a function of radiation dose to the hypothalamus and pituitary in pediatric and young adult patients with brain tumors. J Clin Oncol 36(28):2854–2862PubMedPubMedCentral
191.
Garrahy A, Sherlock M, Thompson CJ (2017) Management of endocrine disease: neuroendocrine surveillance and management of neurosurgical patients. Eur J Endocrinol 176(5):R217–R233PubMed
192.
VanKoevering KK, Sabetsaverstani K, Sullivan SE et al (2020) Pituitary dysfunction after radiation for anterior skull base malignancies: incidence and screening. J Neurol Surg B 81:75–81
Metadaten
Titel
Radiation therapy strategies for skull-base malignancies
verfasst von
J. D. Palmer
M. E. Gamez
K. Ranta
H. Ruiz-Garcia
J. L. Peterson
D. M. Blakaj
D. Prevedello
R. Carrau
A. Mahajan
K. L. Chaichana
D. M. Trifiletti
Publikationsdatum
12.08.2020
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-020-03569-7

Weitere Artikel der Ausgabe 3/2020

Journal of Neuro-Oncology 3/2020 Zur Ausgabe

Topic Review

Management of olfactory neuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma involving the skullbase

Topic Review

Management of squamous cell carcinomas of the skull-base

Clinical Study

Outcomes of sinonasal mucosal melanomas with endoscopic and open resection: a retrospective cohort study

Topic Review

Advances in the management of primary bone sarcomas of the skull base

Topic Review

Reconstruction after open surgery for skull-base malignancies

Topic Review

Reconstruction after endoscopic surgery for skull base malignancies

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise